PYY3-36 First Suppresses Then Stimulates Appetite: A Biphasic Response Not Seen With GLP-1
PYY3-36 produced an initial appetite-suppressing effect followed by a delayed appetite-stimulating rebound in mice, unlike GLP-1 which only suppressed — explaining why PYY-based obesity drugs may have limited duration of effect.
Quick Facts
What This Study Found
PYY3-36 injection produced biphasic appetite response: acute anorexia followed by delayed orexigenic rebound, unlike GLP-1 which showed sustained anorexia — this rebound effect may limit PYY3-36's obesity drug potential compared to GLP-1 agonists.
Key Numbers
How They Did This
animal-study study.
Why This Research Matters
Relevant for neuropeptides, weight-loss.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding PYY3-36 injection produced biphasic appetite response: acute anorexia followed by delayed orexigenic rebound, unlike GLP-1 which showed sustained anor
- Evidence Grade:
- preliminary evidence.
- Study Age:
- Published in 2008.
- Original Title:
- PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones.
- Published In:
- American journal of physiology. Endocrinology and metabolism, 294(4), E698-708 (2008)
- Authors:
- Parkinson, James R C, Dhillo, Waljit S(8), Small, Caroline J(4), Chaudhri, Owais B, Bewick, Gavin A, Pritchard, Iain, Moore, Stanley, Ghatei, Mohammed A, Bloom, Stephen R
- Database ID:
- RPEP-01398
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
PYY3-36 First Suppresses Then Stimulates Appetite: A Biphasic Response Not Seen With GLP-1
What was found?
PYY3-36 produced an initial appetite-suppressing effect followed by a delayed appetite-stimulating rebound in mice, unlike GLP-1 which only suppressed — explaining why PYY-based obesity drugs may have limited duration of effect.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01398APA
Parkinson, James R C; Dhillo, Waljit S; Small, Caroline J; Chaudhri, Owais B; Bewick, Gavin A; Pritchard, Iain; Moore, Stanley; Ghatei, Mohammed A; Bloom, Stephen R. (2008). PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones.. American journal of physiology. Endocrinology and metabolism, 294(4), E698-708. https://doi.org/10.1152/ajpendo.00405.2007
MLA
Parkinson, James R C, et al. "PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones.." American journal of physiology. Endocrinology and metabolism, 2008. https://doi.org/10.1152/ajpendo.00405.2007
RethinkPeptides
RethinkPeptides Research Database. "PYY3-36 injection in mice produces an acute anorexigenic eff..." RPEP-01398. Retrieved from https://rethinkpeptides.com/research/parkinson-2008-pyy336-injection-in-mice
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.